You’ve probably heard a lot about blockchain recently. This system of digital record-keeping, which has been around since 2008, lets people keep track of large numbers of transactions and make chronological entries that are available for public viewing. In fact, blockchain makes cryptocurrencies viable.
In an age when so many people are concerned about digital privacy, it’s good to know that blockchain is extremely secure. It’s virtually hack-proof. Plus, it will only show people your data if you give it permission to, and you can restrict the circumstances under which people can retrieve your information. Thus, blockchain should greatly reduce instances of medical fraud.
Did you realize that this technology is poised to affect a great number of industries, including medicine? Medical visionaries are already dreaming up possibilities. And the supremely talented investor Paul Mampilly is leading the way.
The Benefits of E-Pills
One way that blockchain could impact your health is by telling you whether or not your prescription medications are functioning properly. How would it work? You’d take a pill that’s equipped with digital sensors. That capsule would then send signals to an app on your phone, telling it whether or not the right chemical reactions have occurred inside you. That way, you’d know if your pill was effective or if you needed to see your doctor for a different course of treatment.
Electronic pills will have other advantages. They’ll let doctors know which patients are taking their pills according to schedule and which patients routinely forget their medicine.
Moreover, electronic pills could gather aggregate data about the effectiveness of various drugs. Consequently, medication manufacturers could keep tweaking their products to make them as potent as possible.
If all of these points sound far-fetched to you, you should know that an electronic pill already exists. It’s a medication for schizophrenia and other mental health disorders called Abilify MyCite, and the FDA approved it in 2017.
In addition, medication companies are already starting to study potential e-pill applications. Indeed, many drugmakers believe that this technological breakthrough could make it cheaper for them to create new medications. That’s because they’d have much more data at their disposal during the testing and refining of their prototypes.
Drug companies may also be able to find out which patients take their medications according to the instructions. Imagine that some people started saying that a certain drug doesn’t work. However, it might be the case that those individuals failed to take their pills when they were supposed to. Therefore, drug manufacturers wouldn’t have to deal with as many false claims of ineffectiveness
Here’s the bottom line: If you’re an investor, keep an eye out for opportunities to buy stock in e-pill manufacturers. Likewise, don’t pass up the chance to invest in any companies that make the tiny computer chips that will be attached to those pills.
What Paul Mampilly Knows About Precision Medicine
Paul Mampilly was once a hedge fund manager on Wall Street. For years, members of royal families, major corporations, and many others depended on his uncanny feel for the market. Today, Paul is a manager at two companies that provide assistance with trading and investing: True Momentum and Extreme Fortunes.
In 1996, Paul graduated from Fordham University with a master’s degree in business administration. From there, his career took him to some of the most prestigious investing companies in the world. In 1991, he became an assistant portfolio manager at Bankers Trust, which is now part of Deutsche Bank. He’s also worked at the Royal Bank of Scotland, Deutsche Asset Management, ING, Sears, and Stansberry Research, among other institutions. In 2003, he founded a firm called the Capuchin Group.
On top of all that, Paul Mampilly created Profits Unlimited, a publication that alerts people to promising stocks. He also serves as an editor for Banyan Hill Publishing, a company that specializes in stock market analysis and advice.
When he was 42, Paul “retired.” True, he still keeps up an active work schedule. It’s just that he works for fun now — for the joy of helping other people grow their wealth. He has enough money to lead a luxurious life for many decades to come.
To give you an idea of just how talented Paul is at making investment choices, consider that the firm Kinetics Asset Management hired him in 2006 to take charge of their assets. At that point, they were worth $6 billion. After five years of Paul’s astute management, those assets were valued at $25 billion. Not to mention, during some of that time, a major global recession was raging.
How does Paul do it? What’s his secret to extreme success? Well, to start with, he has an unsurpassed talent for finding little companies that are doing exciting things, organizations that few other investors are paying any attention to. Just when those businesses are ready to explode, Paul is able to swoop in and buy stock in them. At present, Paul is especially enthused about the intersection of blockchain and medicine.
Yes, blockchain technology stands ready to revolutionize medical care in so many ways. It could simplify billing, make patient data much easier to record and manage, increase transparency throughout the industry, reduce overhead for hospitals and clinics, and much more. Through it all, you can be sure that Paul Mampilly will keep anticipating bold new possibilities — and keep making his fans and followers aware of lucrative investment options while he’s at it.
Read this interview with Paul Mampilly on inspirery.com for more information >>